Revista de neurologia · 2000
[Topiramate: a broad spectrum antiepileptic administered to 224 patients with refractory epilepsies].
Оценочное исследованиеСтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Herranz J L
Аннотация
INTRODUCTION: Topiramate (TPM) is a new antiepileptic drug with numerous mechanisms of action and whose references are almost entirely based on the results of clinical trials in selected patients.
OBJECTIVE: To assess the efficacy and tolerability of TPM under the usual conditions of everyday clinical practice, in a multicentric study of unselected patients with all types of uncontrolled epilepsy.
PATIENTS AND METHODS: In 224 patients aged from 4 months to 85 years with uncontrolled epilepsy, we assessed the evolution of their seizures and the appearance of adverse effects when TPM was given.
RESULTS: There was a response to treatment with TPM in 78% of the patients (reduction > 50% of the frequency of seizures) and suppression of seizures in 25% of the cases. The patients responding to treatment with TPM (reduction > 50% of their seizures) included 77% of the patients with partial epilepsy, 83% of those with Lennox-Gastaut syndrome, 79% with multifocal epilepsy, 54% with West's syndrome and 69% of those with other types of epilepsy. Similarly seizures ceased in 31, 13, 15, 15 and 38% of the patients respectively. Although 34% of the patients had adverse effects, suspension of the drug was only necessary in 5% of the cases.
CONCLUSIONS: TPM is a broad-spectrum drug, effective in patients with all types of seizures and epileptic syndromes. It is well tolerated when introduced gradually.
OBJECTIVE: To assess the efficacy and tolerability of TPM under the usual conditions of everyday clinical practice, in a multicentric study of unselected patients with all types of uncontrolled epilepsy.
PATIENTS AND METHODS: In 224 patients aged from 4 months to 85 years with uncontrolled epilepsy, we assessed the evolution of their seizures and the appearance of adverse effects when TPM was given.
RESULTS: There was a response to treatment with TPM in 78% of the patients (reduction > 50% of the frequency of seizures) and suppression of seizures in 25% of the cases. The patients responding to treatment with TPM (reduction > 50% of their seizures) included 77% of the patients with partial epilepsy, 83% of those with Lennox-Gastaut syndrome, 79% with multifocal epilepsy, 54% with West's syndrome and 69% of those with other types of epilepsy. Similarly seizures ceased in 31, 13, 15, 15 and 38% of the patients respectively. Although 34% of the patients had adverse effects, suspension of the drug was only necessary in 5% of the cases.
CONCLUSIONS: TPM is a broad-spectrum drug, effective in patients with all types of seizures and epileptic syndromes. It is well tolerated when introduced gradually.